Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) is scheduled to be announcing its earnings results on Monday, March 20th.
Sensei Biotherapeutics Price Performance
NASDAQ SNSE opened at $1.42 on Friday. The company has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $1.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.95 and a quick ratio of 13.95. The firm has a market capitalization of $43.62 million, a price-to-earnings ratio of -0.97 and a beta of -0.21. Sensei Biotherapeutics has a 52-week low of $1.30 and a 52-week high of $2.86.
Wall Street Analysts Forecast Growth
Separately, Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, December 13th. They issued a “buy” rating for the company.
Hedge Funds Weigh In On Sensei Biotherapeutics
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.
- Get a free copy of the StockNews.com research report on Sensei Biotherapeutics (SNSE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.